8-K: ENDRA Life Sciences Reports 2025 Results, Explores Options

ENDRA Life Sciences announced its Q4 and full-year 2025 financial results, reporting reduced operating expenses and net losses, alongside initiating a strategic alternatives review process.

Summary

• The Board of Directors initiated a process on March 25, 2026, to evaluate strategic alternatives to maximize shareholder value, with no set timetable for completion.
• Positive results from a feasibility study for TAEUS Liver demonstrated accurate quantification of liver fat fraction with a Pearson correlation coefficient of r=0.89.
• TAEUS Liver showed strong concordance with MRI-PDFF, the industry's gold standard, at critical liver fat fraction thresholds of 12-17% and 20-22%.
• Favorable results from a new study reported on February 26, 2026, demonstrated TAEUS's robust intra-user repeatability and inter-user reproducibility, achieving an Intraclass Correlation Coefficient of 0.89.
• Cash used in operations increased to $1.6 million in Q4 2025, compared with $1.5 million in Q4 2024.
• Operating expenses in Q4 2025 decreased to $1.6 million, compared with $4.3 million in Q4 2024.
• Net loss in Q4 2025 was $3.2 million, an improvement from a net loss of $4.2 million in Q4 2024.
• Full-year 2025 operating expenses decreased to $5.8 million, compared with $10.8 million in 2024 (which included a $2.3 million non-cash inventory valuation charge).
• Full-year 2025 net loss was $7.0 million, an improvement from a net loss of $11.5 million in 2024.
• As of December 31, 2025, cash and cash equivalents were approximately $762,000.
• As of December 31, 2025, the company held approximately $2.0 million in its Digital Asset Treasury.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial report, despite operational improvements, due to critically low cash reserves and the initiation of a strategic alternatives review, which often precedes significant corporate restructuring or capital events.

Positives

• Significant reduction in operating expenses for Q4 2025 ($1.6 million) compared to Q4 2024 ($4.3 million).
• Substantial decrease in full-year 2025 operating expenses ($5.8 million) from 2024 ($10.8 million).
• Improved net loss for Q4 2025 ($3.2 million) compared to Q4 2024 ($4.2 million).
• Improved net loss for full-year 2025 ($7.0 million) compared to 2024 ($11.5 million).
• Demonstrated strong clinical progress with TAEUS Liver, showing high accuracy (r=0.89) in quantifying liver fat fraction.
• TAEUS Liver exhibited strong concordance with MRI-PDFF, the industry gold standard, at critical liver fat thresholds.
• TAEUS device achieved robust intra-user repeatability and inter-user reproducibility (ICC of 0.89), essential for long-term monitoring of SLD.
• The company holds $2.0 million in its Digital Asset Treasury as an additional component of its capital management strategy.

Negatives

• Cash and cash equivalents significantly decreased to $762,365 as of December 31, 2025, from $3,229,480 as of December 31, 2024.
• Cash used in operations increased to $1.6 million in Q4 2025, compared with $1.5 million in Q4 2024.
• The company continues to report net losses, despite improvements, with a full-year 2025 net loss of $7.0 million.
• A loss of $995,161 was incurred from the change in fair value of digital assets in 2025.
• The initiation of a strategic alternatives review process, while aimed at maximizing shareholder value, often signals underlying financial challenges or a need for significant change.

Risks

• Expectations regarding the strategic alternative review process and the chance that it may not result in any transaction or other strategic outcome.
• Limited commercial experience, limited cash resources, and a history of losses.
• Ability to obtain adequate financing to fund operations in the future.
• Risks related to shifts in regulatory, accounting, or tax treatment affecting treasury activities.
• Potential impact of any changes in financial reporting requirements.
• The risk that the stock price may be affected by the performance or valuation of assets held in the treasury.
• A determination that the company is an investment company under the Investment Company Act of 1940.
• Ability to achieve profitability.
• Delays or changes in regulatory requirements, policies, or guidelines.
• Potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (FDA) or other regulatory agencies.
• Ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for TAEUS applications.
• Ability to develop commercially viable products based on TAEUS technology.
• Market acceptance of the technology.
• The effect of macroeconomic conditions on the business.
• Results of studies, which may be negative or inconclusive.
• Ability to secure and maintain development partners.
• Reliance on third parties, collaborations, strategic alliances, and licensing arrangements.
• The competitive landscape in the healthcare industry.
• Ability to protect intellectual property.
• Changes in healthcare industry practices or reimbursement policies.
• Ability to comply with regulations from federal, state, local, and foreign governmental agencies.
• Ability to maintain compliance with Nasdaq listing standards.
• Dependence on key members of management.

Future Outlook

The company intends to continue executing on its strategic and operating initiatives during the strategic alternatives review process, which has no set timetable for completion. Management remains highly confident in the long-term potential of TAEUS and optimistic about its value to patients, clinicians, and shareholders.

Management Comments

• "Over the past year we significantly strengthened the clinical foundation for TAEUS, demonstrating performance that we believe positions our technology alongside the current standard of care, while maintaining the accessibility, scalability and cost of handheld ultrasound systems." Alexander Tokman, ENDRA's Chief Executive Officer.
• "We remain highly confident in the long-term potential of TAEUS and are optimistic about the value it can deliver to patients, clinicians and our shareholders." Alexander Tokman, ENDRA's Chief Executive Officer.
• "As we evaluate strategic alternatives for the company, our focus is on ensuring that this progress translates into maximum benefit for all stakeholders." Alexander Tokman, ENDRA's Chief Executive Officer.

Industry Context

StockSavvy.ai notes that the market for non-invasive liver fat assessment, particularly for steatotic liver disease (SLD), is substantial, affecting over two billion people globally. ENDRA's TAEUS Liver, with its demonstrated concordance to MRI-PDFF (the industry gold standard) and robust repeatability, positions it as a potentially disruptive technology. The focus on accessibility, scalability, and cost-effectiveness could allow it to capture a significant share in routine clinical practice and pharmaceutical trials, where current solutions may be more expensive or less accessible.

Comparison to Industry Standards

• TAEUS Liver's Pearson correlation coefficient of r=0.89 for quantifying liver fat fraction across full stages of steatotic disease and BMIs compares favorably to other non-invasive methods, aiming to rival the accuracy of MRI-PDFF.
• The device's strong concordance with MRI-PDFF at critical liver fat fraction thresholds (12-17% and 20-22%) positions it as a viable alternative or complementary tool to the current gold standard for non-invasive liver fat assessment.
• An Intraclass Correlation Coefficient (ICC) of 0.89 with a standard error of measurement of 3.3% for intra-user repeatability and inter-user reproducibility is a strong indicator of reliability, crucial for long-term monitoring of chronic conditions like SLD, and is competitive with other diagnostic imaging modalities.

Stakeholder Impact

• Shareholders face potential for value maximization through strategic alternatives, but also significant risk of dilution or unfavorable outcomes given the company's precarious financial position.
• Patients and clinicians could benefit from the TAEUS Liver technology for early detection and monitoring of SLD, offering an accessible, scalable, and cost-effective diagnostic tool.
• Employees may experience uncertainty related to the strategic alternatives review process and the company's future direction.
• Creditors' positions could be impacted depending on the outcome of the strategic alternatives review and the company's ability to secure future financing.

Next Steps

• Continue executing on strategic and operating initiatives during the strategic alternatives review process.
• The strategic alternatives review process has no set timetable for completion.
• Potential deployment of TAEUS Liver in routine clinical practice.
• Potential utilization of TAEUS Liver by pharmaceutical companies for patient recruitment and follow-up in clinical trials.

Key Dates

Recommendation

The company's cash position is critically low ($762,000) and cash used in operations increased in Q4 2025. While operating expenses and net losses improved, the initiation of a strategic alternatives review, coupled with limited cash and a history of losses, signals significant financial distress and a high probability of substantial dilution or an unfavorable outcome for current shareholders. The positive clinical progress is overshadowed by the immediate financial viability concerns.

Keywords

ENDRA Life Sciences, NDRA, Financial Results, Q4 2025, Full Year 2025, Strategic Alternatives, TAEUS Liver, Steatotic Liver Disease, SLD, MASLD, MASH, Thermoacoustic Biomarker Imaging, Medical Devices, Biotechnology, Liver Fat Quantification, MRI-PDFF, Clinical Trials, Nasdaq Listing